Compounds > ofloxacin
Page last updated: 2024-11-01

ofloxacin and Disease Models, Animal

ofloxacin has been researched along with Disease Models, Animal in 119 studies

Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.

Research Excerpts

ExcerptRelevanceReference
"To evaluate the antibacterial and anti-inflammatory effects of kolaviron on albino Wistar rats induced with pneumonia using Klebsiella pneumonia."8.02Effects of Kolaviron on Pneumonia-like Infection Induced in Albino Wistar Rats. ( Catherine, OF; Dozie, NC; Dozie-Nwakile, OC; Felicia, ON; Kingsley, UI, 2021)
"Levofloxacin cures established pneumonic plague when treatment is initiated after the onset of fever in the lethal aerosol-challenged AGM nonhuman primate model, and can be considered for treatment of other forms of plague."7.77Levofloxacin cures experimental pneumonic plague in African green monkeys. ( Barr, EB; Brasel, TL; Gigliotti, AP; Koster, F; Layton, RC; McDonald, JD; Mega, W, 2011)
"5% levofloxacin in rabbits, and to determine its improved efficacy against experimental keratitis."7.76Novel mucoadhesive polysaccharide isolated from Bletilla striata improves the intraocular penetration and efficacy of levofloxacin in the topical treatment of experimental bacterial keratitis. ( Chen, H; Jiang, HR; Wu, XG; Xin, M; Yang, LN, 2010)
"3% ofloxacin solution) on methicillin-resistant Staphylococcus aureus (MRSA) keratitis were compared in a rabbit model."7.73Antibiotic effects of WP-0405, a thermo-setting ofloxacin gel, on methicillin-resistant Staphylococcus aureus keratitis in rabbits. ( Fukaya, Y; Hirata, H; Kamata, Y; Kambara, Y; Kurasawa, N; Kurita, A; Naito, A; Nakaya, S; Ohashi, Y; Sato, M; Shirasawa, E; Toyoda, Y; Tsuruga, H; Wada, T, 2006)
"A dose-decreasing immunocompetent sepsis mouse model was used to evaluate the in vivo effect of levofloxacin, moxifloxacin and gemifloxacin, using a ciprofloxacin/levofloxacin susceptible serotype 6B strain (ciprofloxacin MIC: 1 mg/l) and two resistant serotype 14 and 19F strains with gyrA and parC point mutations (ciprofloxacin MICs of 32 and 64 mg/l, respectively)."7.73In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. ( Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D, 2005)
"Taurolidine is a broad-spectrum, non antibiotic antimicrobial agent, not previously tested against the common causes of bacterial keratitis."7.73Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model. ( Gurkan, T; Oguz, E; Oguz, H; Ozbilge, H, 2005)
"Molecular detection of rifampin resistance (rpoB analysis) in Mycobacterium leprae was determined for 49 patients who experienced relapse of multibacillary leprosy and for 34 untreated patients."7.71Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. ( Bonnafous, P; Cambau, E; Jarlier, V; Ji, B; Perani, E; Sougakoff, W, 2002)
"Strains of the plague microbe, antigen complete and defective by fraction I and mouse toxin had the same in vitro susceptibility to ofloxacin (MIC 0."7.71[Ofloxacin efficacy in the prophylaxis and treatment of experimental plague due to antigen complete and defective strains of the pathogen]. ( Ryzhko, IV; Samokhodkina, ED; Shcherbaniuk, AI; Skalyga, EIu; Tsuraeva, RI, 2002)
"To compare the antibacterial effect of povidone-iodine (PI) with that of ofloxacin in an experimental model of bacterial keratitis."7.70Effect of topical povidone-iodine versus topical ofloxacin on experimental Staphylococcus keratitis. ( Goldberg, MA; Lustbader, J; MacDowell, AL; Melki, SA; Safar, A; Scharper, M; Scharper, P; Yaghouti, F; Zeligs, B, 2000)
"Topical treatment of experimental Staphylococcus keratitis with ciprofloxacin-PSS, ciprofloxacin, or ofloxacin was effective."7.70Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model. ( Engel, LS; Green, LC; Hill, JM; Moreau, JM; O'Callaghan, RJ, 1998)
"Ofloxacin, a new antibiotic of the group of quinolones, was tested for its possible cocataractogenic potential."7.68Evaluation of a possible cocataractogenic potential of Ofloxacin. ( Hockwin, O; Kuhn, UD; Lorenz, M; Wegener, A, 1990)
"The bactericidal activities against Mycobacterium leprae of single or multiple doses of various combinations of new antileprosy drugs [minocycline (MINO), clarithromycin (CLARI), ofloxacin (OFLO), and sparfloxacin (SPFX)] and/or rifampin (RMP) were titrated in immunocompetent mice by the proportional bactericidal method."7.68Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice. ( Grosset, JH; Ji, B; Perani, EG; Petinon, C, 1992)
"We have compared the efficacy of temafloxacin against Streptococcus pneumoniae in experimental murine pneumonia models with that of ofloxacin and ciprofloxacin."7.68Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafloxacin. ( Azoulay-Dupuis, E; Bedos, JP; Pocidalo, JJ; Vallée, E, 1991)
"The chemotherapeutic efficacy of ofloxacin against experimental pneumonia was investigated with special reference to its treatment regimen."7.67Chemotherapeutic efficacy of ofloxacin against experimental pneumonia with Pseudomonas aeruginosa in guinea pigs. ( Hashimoto, S; Iigo, Y; Ishida, Y; Nakajima, R; Osada, Y; Otani, T; Une, T, 1989)
"To evaluate the antibacterial and anti-inflammatory effects of kolaviron on albino Wistar rats induced with pneumonia using Klebsiella pneumonia."4.02Effects of Kolaviron on Pneumonia-like Infection Induced in Albino Wistar Rats. ( Catherine, OF; Dozie, NC; Dozie-Nwakile, OC; Felicia, ON; Kingsley, UI, 2021)
"Levofloxacin cures established pneumonic plague when treatment is initiated after the onset of fever in the lethal aerosol-challenged AGM nonhuman primate model, and can be considered for treatment of other forms of plague."3.77Levofloxacin cures experimental pneumonic plague in African green monkeys. ( Barr, EB; Brasel, TL; Gigliotti, AP; Koster, F; Layton, RC; McDonald, JD; Mega, W, 2011)
"5% levofloxacin in rabbits, and to determine its improved efficacy against experimental keratitis."3.76Novel mucoadhesive polysaccharide isolated from Bletilla striata improves the intraocular penetration and efficacy of levofloxacin in the topical treatment of experimental bacterial keratitis. ( Chen, H; Jiang, HR; Wu, XG; Xin, M; Yang, LN, 2010)
"To compare the therapeutic effectiveness of a single intrastromal dose of gentamycin, tobramycin, ciprofloxacin and ofloxacin for the treatment of corneal ulcers due to Pseudomonas aeruginosa."3.75[Bacterial corneal ulcer treated with intrastromal antibiotic. Experimental model in vivo]. ( Naranjo-Tackman, R; Stangogiannis-Druya, C; Stangogiannis-Druya, E; Vanzzini, V; Villar-Kurí, J, 2009)
"3% ofloxacin solution) on methicillin-resistant Staphylococcus aureus (MRSA) keratitis were compared in a rabbit model."3.73Antibiotic effects of WP-0405, a thermo-setting ofloxacin gel, on methicillin-resistant Staphylococcus aureus keratitis in rabbits. ( Fukaya, Y; Hirata, H; Kamata, Y; Kambara, Y; Kurasawa, N; Kurita, A; Naito, A; Nakaya, S; Ohashi, Y; Sato, M; Shirasawa, E; Toyoda, Y; Tsuruga, H; Wada, T, 2006)
" Recently, the use of high doses of levofloxacin with rifampin has been recommended for staphylococcal infections."3.73Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. ( Ariza, J; Cabellos, C; Doménech, A; Garcia, A; Gudiol, F; Murillo, O; Tubau, F, 2006)
"A dose-decreasing immunocompetent sepsis mouse model was used to evaluate the in vivo effect of levofloxacin, moxifloxacin and gemifloxacin, using a ciprofloxacin/levofloxacin susceptible serotype 6B strain (ciprofloxacin MIC: 1 mg/l) and two resistant serotype 14 and 19F strains with gyrA and parC point mutations (ciprofloxacin MICs of 32 and 64 mg/l, respectively)."3.73In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. ( Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D, 2005)
"Taurolidine is a broad-spectrum, non antibiotic antimicrobial agent, not previously tested against the common causes of bacterial keratitis."3.73Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model. ( Gurkan, T; Oguz, E; Oguz, H; Ozbilge, H, 2005)
"In a fibrin-clot model of sepsis, developed in mice, treatment with the antibiotics ceftazidime (Cfz) and ofloxacin (Ofl) caused significant (p < 0."3.73Antibiotic-induced release of inflammatory mediators from bacteria in experimental Klebsiella pneumoniae-induced sepsis. ( Bramhne, HG; Chhibber, S; Sharma, S; Toky, V, 2005)
"The fourth-generation fluoroquinolone, gatifloxacin, is an effective prophylaxis against the development of keratitis after lamellar keratectomy in rabbits with an organism resistant to methicillin, levofloxacin, and ciprofloxacin."3.72Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model. ( Carpenter, TR; Kaufman, MB; McDonnell, PJ; Sarayba, MA; Sweet, PM; Taban, M; Tungsiripat, T, 2003)
"Molecular detection of rifampin resistance (rpoB analysis) in Mycobacterium leprae was determined for 49 patients who experienced relapse of multibacillary leprosy and for 34 untreated patients."3.71Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. ( Bonnafous, P; Cambau, E; Jarlier, V; Ji, B; Perani, E; Sougakoff, W, 2002)
"Strains of the plague microbe, antigen complete and defective by fraction I and mouse toxin had the same in vitro susceptibility to ofloxacin (MIC 0."3.71[Ofloxacin efficacy in the prophylaxis and treatment of experimental plague due to antigen complete and defective strains of the pathogen]. ( Ryzhko, IV; Samokhodkina, ED; Shcherbaniuk, AI; Skalyga, EIu; Tsuraeva, RI, 2002)
"To compare the antibacterial effect of povidone-iodine (PI) with that of ofloxacin in an experimental model of bacterial keratitis."3.70Effect of topical povidone-iodine versus topical ofloxacin on experimental Staphylococcus keratitis. ( Goldberg, MA; Lustbader, J; MacDowell, AL; Melki, SA; Safar, A; Scharper, M; Scharper, P; Yaghouti, F; Zeligs, B, 2000)
"Topical treatment of experimental Staphylococcus keratitis with ciprofloxacin-PSS, ciprofloxacin, or ofloxacin was effective."3.70Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model. ( Engel, LS; Green, LC; Hill, JM; Moreau, JM; O'Callaghan, RJ, 1998)
"Ofloxacin (OFLX), having superior antileprosy activity among the various quinolones, was studied for its combined therapeutic efficacy with rifampin (RMP) against Mycobacterium leprae infection induced in nude mice."3.68Therapeutic efficacy of some new quinolones and a combination of ofloxacin with rifampin against Mycobacterium leprae infection induced in athymic nude mice. ( Saito, H; Tomioka, H, 1993)
"The bactericidal activities against Mycobacterium leprae of single or multiple doses of various combinations of new antileprosy drugs [minocycline (MINO), clarithromycin (CLARI), ofloxacin (OFLO), and sparfloxacin (SPFX)] and/or rifampin (RMP) were titrated in immunocompetent mice by the proportional bactericidal method."3.68Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice. ( Grosset, JH; Ji, B; Perani, EG; Petinon, C, 1992)
"We have compared the efficacy of temafloxacin against Streptococcus pneumoniae in experimental murine pneumonia models with that of ofloxacin and ciprofloxacin."3.68Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafloxacin. ( Azoulay-Dupuis, E; Bedos, JP; Pocidalo, JJ; Vallée, E, 1991)
"Ofloxacin, a new antibiotic of the group of quinolones, was tested for its possible cocataractogenic potential."3.68Evaluation of a possible cocataractogenic potential of Ofloxacin. ( Hockwin, O; Kuhn, UD; Lorenz, M; Wegener, A, 1990)
"The chemotherapeutic efficacy of ofloxacin against experimental pneumonia was investigated with special reference to its treatment regimen."3.67Chemotherapeutic efficacy of ofloxacin against experimental pneumonia with Pseudomonas aeruginosa in guinea pigs. ( Hashimoto, S; Iigo, Y; Ishida, Y; Nakajima, R; Osada, Y; Otani, T; Une, T, 1989)
"Ofloxacin, a new pyridone-carboxylic acid derivative, was evaluated in descending nephritis and subcutaneous abscess models with Staphylococcus aureus in mice in comparison with norfloxacin."3.67Chemotherapeutic efficacy of ofloxacin on renal and subcutaneous infection models with Staphylococcus aureus in mice. ( Fujimoto, T; Katami, K; Osada, Y; Sato, M; Tachizawa, H; Tsumura, M; Une, T, 1986)
"Ofloxacin treatment failed to counter the bacterial proliferation in Pyn-STm coinfected mice."1.48Plasmodium-Salmonella Coinfection Induces Intense Inflammatory Response, Oxidative Stress, and Liver Damage: A Mice Model Study for Therapeutic Strategy. ( Maurya, AK; Mittal, S; Pal, A; Pandey, AK; Patel, DK; Singh, D; Tiwari, N, 2018)
"Levofloxacin was administered daily beginning at 6 to 12 h postexposure for 7 treatments."1.38Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax. ( Bourdage, JS; Duchars, M; Fuerst, TR; Fusco, PC; Leffel, EK; Williamson, ED, 2012)
"Verapamil and reserpine were included to determine their effect on rifampicin and ofloxacin susceptibility."1.37Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. ( Gey van Pittius, NC; Grobbelaar, M; Hernandez-Pando, R; Jimenez, A; Leon, R; Louw, GE; McEvoy, CR; Murray, M; van Helden, PD; Victor, TC; Warren, RM, 2011)
" Subsequently, a neutropenic murine pneumonia model with simulated clinical dosing exposures was used to validate our quantitative assessment of combined killing."1.36Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. ( Hou, J; Ledesma, KR; Prince, RA; Singh, R; Tam, VH; Yuan, Z, 2010)
"Levofloxacin 1."1.36Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models. ( Gordon, YJ; Kowalski, RP; Mah, FS; Romanowski, EG; Shanks, RM, 2010)
" The superiority of aerosol dosing over systemic dosing was demonstrated in models of both acute and chronic lung infection."1.35Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. ( Dudley, MN; Griffith, DC; Miller, CE; Nolan, TG; Sabet, M; Senekeo-Effenberger, K, 2009)
"Levofloxacin was more efficient than cloxacillin (P < 0."1.35Intracellular antimicrobial activity appearing as a relevant factor in antibiotic efficacy against an experimental foreign-body infection caused by Staphylococcus aureus. ( Ariza, J; Cabellos, C; Cabo, J; Carreras, M; Euba, G; Gudiol, F; Murillo, O; Pachón, ME; Verdaguer, R, 2009)
"In a parallel study with the pneumonic plague mouse model, after 72 h postinfection, the lungs of animals infected with wild-type (WT) Y."1.35Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague. ( Agar, SL; Baze, WB; Chauhan, S; Chopra, AK; Erova, TE; Fadl, AA; Foltz, SM; Klimpel, GR; Motin, VL; Olano, JP; Peterson, JW; Sha, J; Suarez, G; Wang, S, 2008)
" These results, including in vitro antibacterial activity against clinical isolates and therapeutic efficacy of a humanized dosing regimen, provide good evidence to support the use of LVFX at 500 mg once a day for treating patient with legionnaires disease."1.35[Therapeutic efficacy of levofloxacin against a model of replicable Legionella pneumophila lung infection in DBA/2 mice]. ( Fujikawa, K; Karibe, Y; Kashimoto, Y; Kurosaka, Y; Namba, K; Otani, T; Uoyama, S; Yamaguchi, K, 2009)
"Levofloxacin treatment had no effect on IL-6 activities and concentrations in uninfected broilers."1.34Role of interleukin-6 in the pathogenesis of an avian model of Staphylococcus aureus arthritis. ( Cheng, GF; Gu, CQ; Hu, XY; Li, XM; Wang, DH; Zhou, Q; Zhou, SQ, 2007)
" The aim of this study was to compare the therapeutic efficacy of quinupristin-dalfopristin (QD) alone, or in combination with gentamicin (G), teicoplanin (T), imipenem (I) or levofloxacin (L) against a strain of multidrug-resistant E."1.33[Comparative study of treatment with quinupristin-dalfopristin alone or in combination with gentamicin, teicoplanin, imipenem or levofloxacin in experimental endocarditis due to a multidrug-resistant Enterococcus faecium]. ( Gómez Gómez, J; López Fornás, F; Lorente Salinas, I; Martínez García, F; Pérez Salmerón, J; Roldán Conesa, D; Ruiz Gómez, J; Segovia Hernández, M; Valdés Chávarri, M, 2006)
" In these strains, levofloxacin ED(50)s were 2- to 10-fold lower than the ED(50)/MIC ratios in the other strains and 90% E(max) AUC/MIC ratios were 2- to 4-fold lower than those predicted from pharmacodynamic modeling of efficacy against other strains."1.33Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy? ( Cho, D; Corcoran, E; Dudley, MN; Griffith, DC; Lee, A; Lofland, D; Lomovskaya, O, 2006)
"For levofloxacin-treated mice, 2 of 7 (29%) isolates with a levofloxacin minimum inhibitory concentration (MIC) 4 times that of the infecting parent strain had ParC mutations."1.33Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice. ( Bast, DJ; de Azavedo, JC; Dresser, L; Duncan, CL; Low, DE; Mandell, LA; Walker, SE, 2006)
" CAZ combined with LVX or AMK yielded Fls indicating synergism (Fl < or = 0."1.33In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa. ( Felici, A; Guerrini, M; Marchetti, F; Piccoli, L, 2005)
"We evaluated the in vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia using a susceptible strain and one with low-level resistance (MIC/MBC of levofloxacin: 0."1.31In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia. ( Bryskier, A; Carbon, C; Farinotti, R; Joly-Guillou, ML; Wolff, M, 2000)
"Moxifloxacin has a greater bactericidal rate as determined by regression of log CFU versus time data."1.31Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. ( Bui, KQ; Mattoes, H; McNabb, J; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D; Zhong, M, 2001)
" The elimination half-life in plasma and CSF was calculated using non-linear regression analysis."1.31Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. ( Dash, AK; Destache, CJ; Larsen, C; Owens, H; Pakiz, CB, 2001)
" Only the group treated with quinupristin/dalfopristin combined with levofloxacin or doxycycline showed no evidence of staphylococcal infection."1.31Quinupristin/dalfopristin bonding in combination with intraperitoneal antibiotics prevent infection of knitted polyester graft material in a subcutaneous rat pouch model infected with resistant Staphylococcus epidermidis. ( Cirioni, O; D'Amato, G; Del Prete, M; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G, 2002)
"The efficacy of two polymyxin-like peptides, KFFKFFKFF and IKFLKFLKFL, alone and combined with levofloxacin, was investigated in a rat model of septic shock."1.31Therapeutic efficacy of intraperitoneal polymyxin B and polymyxin-like peptides alone or combined with levofloxacin in rat models of septic shock. ( Cirioni, O; Ghiselli, R; Giacometti, A; Kamysz, W; Kasprzykowski, F; Mackiewicz, Z; Mocchegiani, F; Orlando, F; Paggi, AM; Saba, V; Scalise, G, 2002)
"Levofloxacin (L-ofloxacin) is a fluoroquinolone derivative."1.30Successful treatment of murine listeriosis and salmonellosis with levofloxacin. ( Bornitz, F; Hof, H; Kretschmar, M; Nichterlein, T, 1998)
" The dosing regimen of each drug that yielded serum levels in mice which mimic human therapeutic concentrations of the drugs, were designed."1.30Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. ( Bui, KQ; Nicolau, DP; Nightingale, CH; Onyeji, CO; Owens, RC; Quintiliani, R, 1999)
"Sparfloxacin at 100 mg/kg was more active than LEV at 200 mg/kg; however, the activities of sparfloxacin at 50 mg/kg and LEV at 200 mg/kg were comparable."1.29Activity of levofloxacin in a murine model of tuberculosis. ( Cynamon, MH; Klemens, SP; Rogge, MC; Sharpe, CA, 1994)
"We studied the pharmacokinetic parameters of four fluoroquinolones--ofloxacin, ciprofloxacin, temafloxacin and sparfloxacin--in a mouse model of Streptococcus pneumoniae-infected lung."1.28Pharmacokinetics of four fluoroquinolones in an animal model of infected lung. ( Azoulay-Dupuis, E; Bergogne-Bérézin, E; Pocidalo, JJ; Vallée, E, 1991)
"Ofloxacin and enoxacin were administered per os and pefloxacin and ciprofloxacin were injected subcutaneously."1.28[Activity of fluoroquinolones studied on a model of suppurative meningoencephalitis caused by Pseudomonas aeruginosa in mice]. ( Mnatsakanian, VE; Padeĭskaia, EN, 1991)
"Treatment with ofloxacin and ciprofloxacin at 50 mg/kg 18 h after infection did not significantly increase survival rates compared with those of untreated controls."1.28Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. ( Azoulay-Dupuis, E; Bedos, JP; Hardy, DJ; Pocidalo, JJ; Swanson, RN; Vallée, E, 1991)

Research

Studies (119)

TimeframeStudies, this research(%)All Research%
pre-19902 (1.68)18.7374
1990's24 (20.17)18.2507
2000's62 (52.10)29.6817
2010's25 (21.01)24.3611
2020's6 (5.04)2.80

Authors

AuthorsStudies
Avdeef, A1
Tam, KY1
Redondo, M1
Zarruk, JG1
Ceballos, P1
Pérez, DI1
Pérez, C1
Perez-Castillo, A1
Moro, MA1
Brea, J1
Val, C1
Cadavid, MI1
Loza, MI2
Campillo, NE1
Martínez, A1
Gil, C1
Solinski, HJ1
Dranchak, P1
Oliphant, E1
Gu, X1
Earnest, TW1
Braisted, J1
Inglese, J1
Hoon, MA1
Abrams, RPM1
Yasgar, A1
Teramoto, T1
Lee, MH1
Dorjsuren, D1
Eastman, RT1
Malik, N1
Zakharov, AV1
Li, W3
Bachani, M1
Brimacombe, K1
Steiner, JP1
Hall, MD1
Balasubramanian, A1
Jadhav, A1
Padmanabhan, R1
Simeonov, A1
Nath, A1
Turcu, AL1
Companys-Alemany, J1
Phillips, MB1
Patel, DS1
Griñán-Ferré, C1
Brea, JM1
Pérez, B1
Soto, D1
Sureda, FX1
Kurnikova, MG1
Johnson, JW1
Pallàs, M1
Vázquez, S1
Khomtchouk, KM2
Kouhi, A2
Xia, A2
Bekale, LA1
Massa, SM1
Sweere, JM1
Pletzer, D2
Hancock, RE1
Bollyky, PL2
Santa Maria, PL2
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Li, X10
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Zhang, S2
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Zhou, L2
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y1
Chen, Y3
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Wang, J4
Zhang, E1
Zhang, J3
Li, Y6
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Wang, Y2
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L2
Liu, X1
Ren, Y1
Li, J7
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C3
Zhou, X2
Wang, W1
Wang, S4
Hou, J2
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhu, J2
Zhang, L2
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Wang, X6
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y4
Wu, X1
Lu, J2
Li, M1
Wu, W1
Du, F1
Ji, H1
Yang, X2
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S1
Zhang, M4
Zhang, H1
Yang, T2
Dong, Y1
Xu, Y1
Yuan, Z2
Cao, J1
Zheng, Y2
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z2
Liang, C1
Yang, H1
Song, Y1
Yu, K1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Wang, H4
Liu, Y4
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Wang, Q2
Rathore, MG1
Reddy, K1
Chen, H2
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C3
Gao, F1
Qi, Y1
Lu, H1
Zhang, X5
Cai, X1
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C1
Chen, W2
Hu, X1
Zhang, F1
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D2
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y3
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H1
He, Z1
Chen, B1
Wu, J1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X3
Duong, F1
Kong, W1
Chang, JH1
Sun, J1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D2
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Dozie-Nwakile, OC1
Dozie, NC1
Kingsley, UI1
Catherine, OF1
Felicia, ON1
Joseph, LI1
Khomtchouk, BB1
Massa, S1
Koliesnik, I1
Patel, DK1
Mittal, S1
Tiwari, N1
Maurya, AK1
Pandey, AK1
Pal, A1
Chu, F1
Gu, H1
Dahlgren, RA1
Ahmad, Z1
Tyagi, S1
Minkowski, A1
Peloquin, CA1
Grosset, JH2
Nuermberger, EL1
Bernard, C1
Aubry, A1
Chauffour, A1
Brossier, F1
Robert, J1
Veziris, N1
Dey, S1
Bishayi, B1
Muller-Serieys, C1
Saleh Mghir, A1
Massias, L1
Fantin, B1
Stangogiannis-Druya, E1
Stangogiannis-Druya, C1
Naranjo-Tackman, R1
Vanzzini, V1
Villar-Kurí, J1
Louie, A2
Fregeau, C1
Liu, W2
Kulawy, R1
Drusano, GL2
Sabet, M1
Miller, CE1
Nolan, TG1
Senekeo-Effenberger, K1
Dudley, MN2
Griffith, DC2
Murillo, O2
Pachón, ME1
Euba, G1
Verdaguer, R1
Carreras, M1
Cabellos, C2
Cabo, J1
Gudiol, F2
Ariza, J2
Ryzhko, IV2
Tsuraeva, RI2
Anisimov, BI1
Trishina, AV1
Kashimoto, Y1
Kurosaka, Y1
Karibe, Y1
Uoyama, S1
Fujikawa, K1
Namba, K1
Otani, T2
Yamaguchi, K3
Ledesma, KR1
Singh, R1
Prince, RA1
Tam, VH1
Hart, E1
Azzopardi, K1
Taing, H1
Graichen, F1
Jeffery, J1
Mayadunne, R1
Wickramaratna, M1
O'Shea, M1
Nijagal, B1
Watkinson, R1
O'Leary, S1
Finnin, B1
Tait, R1
Robins-Browne, R1
Kowalski, RP1
Romanowski, EG2
Mah, FS2
Shanks, RM1
Gordon, YJ2
Wu, XG1
Xin, M1
Yang, LN1
Jiang, HR1
Truusalu, K1
Kullisaar, T1
Hütt, P1
Mahlapuu, R1
Aunapuu, M1
Arend, A1
Zilmer, M1
Mikelsaar, RH1
Mikelsaar, M1
Sato, T1
Tateda, K2
Kimura, S2
Ishii, Y2
Layton, RC1
Mega, W1
McDonald, JD1
Brasel, TL1
Barr, EB1
Gigliotti, AP1
Koster, F1
Louw, GE1
Warren, RM1
Gey van Pittius, NC1
Leon, R1
Jimenez, A1
Hernandez-Pando, R1
McEvoy, CR1
Grobbelaar, M1
Murray, M1
van Helden, PD1
Victor, TC1
Shi, G1
Guo, X1
Sokolova, GB1
Maliev, BM1
Mozhokina, GN1
Elistratova, NA1
Solov'eva, IP1
Bugaenko, SE1
Saribas, Z1
Ergun, H1
Mamuk, S1
Köseoglu-Eser, O1
Melli, M1
Mori, N1
Kouyama, Y1
Inoko, H1
Mitsunaga, S1
Yoshihara, E1
Leffel, EK1
Bourdage, JS1
Williamson, ED1
Duchars, M1
Fuerst, TR1
Fusco, PC1
Dong, LY1
Wang, CY1
Wu, CQ1
Jiang, Q1
Zhang, ZF1
Sha, J2
Rosenzweig, JA1
Kirtley, ML1
van Lier, CJ1
Fitts, EC1
Kozlova, EV1
Erova, TE2
Tiner, BL1
Chopra, AK2
Tasaka, Y1
Suzuki, T1
Kawasaki, S1
Uda, T1
Mito, T1
Uno, T1
Ohashi, Y2
Corey, A1
Migone, TS1
Bolmer, S1
Fiscella, M1
Ward, C1
Chen, C1
Meister, G1
Durek, C1
Jurczok, A1
Werner, H1
Jocham, D1
Bohle, A1
Croisier, D1
Chavanet, P1
Lequeu, C1
Ahanou, A1
Nierlich, A1
Neuwirth, C1
Piroth, L1
Duong, M1
Buisson, M1
Portier, H1
Ghiselli, R2
Giacometti, A2
Cirioni, O2
Mocchegiani, F2
Orlando, F2
Del Prete, M1
D'Amato, G1
Scalise, G2
Saba, V2
Holzer, MP1
Sandoval, HP1
Vargas, LG1
Kasper, TJ1
Vroman, DT1
Apple, DJ1
Solomon, KD1
Rubinstein, E1
Hiramatsu, K1
Murakami, J1
Kishi, K1
Hirata, N1
Yamasaki, T1
Kadota, J2
Shibata, T1
Nasu, M1
Tungsiripat, T1
Sarayba, MA2
Kaufman, MB1
Sweet, PM2
Taban, M2
Carpenter, TR1
McDonnell, PJ5
Cottagnoud, P1
Cottagnoud, M1
Acosta, F1
Flatz, L1
Kühn, F1
Stucki, A1
Entenza, J1
Lee, EJ1
Truong, TN1
Mendoza, MN1
Fleiszig, SM1
Barequet, IS1
Denton, P1
Osterhout, GJ1
Tuli, S1
O'Brien, TP1
Thadepalli, H1
Chuah, SK1
Gollapudi, S1
Bast, DJ2
Yue, M1
Bell, D1
Dresser, L2
Saskin, R1
Mandell, LA2
Low, DE2
de Azavedo, JC2
Bauhofer, A1
Celik, I1
Plaul, U1
Wulf, H1
Torossian, A1
Alkorta, M1
Giménez, MJ1
Vicente, D1
Aguilar, L1
Pérez-Trallero, E1
Oguz, H2
Ozbilge, H1
Oguz, E1
Gurkan, T1
Shamie, N1
Reiser, BJ1
Graff, JM1
Kesler-Diaz, A1
Osann, KE1
Toky, V1
Sharma, S1
Bramhne, HG1
Chhibber, S1
Samokhodkina, ED1
Shcherbaniuk, AI1
Skalyga, EIu1
Piccoli, L1
Guerrini, M1
Felici, A1
Marchetti, F1
Hung, CR1
Caballero, AR1
Marquart, ME1
O'Callaghan, RJ2
Thibodeaux, BA1
Johnston, KH1
Dajcs, JJ1
Huelves, L1
Sevillano, D1
Martínez-Marín, C1
López-Casla, MT1
Gracia, M1
Alou, L1
del Carmen Ponte, M1
Prieto, J1
Soriano, F1
Dhaliwal, DK1
Yates, KA1
Corcoran, E1
Lofland, D1
Lee, A1
Cho, D1
Lomovskaya, O1
Yağci, R1
Oflu, Y1
Dinçel, A1
Kaya, E1
Yağci, S1
Bayar, B1
Duman, S1
Bozkurt, A1
Mecikoglu, M1
Saygi, B1
Yildirim, Y1
Karadag-Saygi, E1
Ramadan, SS1
Esemenli, T1
Fukaya, Y1
Kurita, A1
Tsuruga, H1
Naito, A1
Nakaya, S1
Sato, M2
Kamata, Y1
Hirata, H1
Kambara, Y1
Kurasawa, N1
Wada, T1
Toyoda, Y1
Shirasawa, E1
Doménech, A1
Garcia, A1
Tubau, F1
Pérez Salmerón, J1
Martínez García, F1
Roldán Conesa, D1
Lorente Salinas, I1
López Fornás, F1
Ruiz Gómez, J1
Gómez Gómez, J1
Segovia Hernández, M1
Valdés Chávarri, M1
Wormser, GP1
Filozov, A1
Telford, SR1
Utpat, S1
Kamer, RS1
Liveris, D1
Wang, G1
Zentmaier, L1
Schwartz, I1
Aguero-Rosenfeld, ME1
Duncan, CL1
Walker, SE1
Heine, HS1
Bassett, J1
Miller, L1
Hartings, JM1
Ivins, BE1
Pitt, ML1
Fritz, D1
Norris, SL1
Byrne, WR2
Milberg, P1
Hilker, E1
Ramtin, S1
Cakir, Y1
Stypmann, J1
Engelen, MA1
Mönnig, G1
Osada, N1
Breithardt, G1
Haverkamp, W1
Eckardt, L1
Griffith, ME1
Moon, JE1
Johnson, EN1
Clark, KP1
Hawley, JS1
Hospenthal, DR1
Murray, CK1
Zhou, Q1
Gu, CQ1
Hu, XY1
Wang, DH1
Li, XM1
Zhou, SQ1
Cheng, GF1
Trampuz, A1
Murphy, CK1
Rothstein, DM1
Widmer, AF1
Landmann, R1
Zimmerli, W1
Deziel, MR1
Shaw, PJ1
Hopfensperger, MJ1
Ganey, PE1
Roth, RA1
Bao, D1
Truong, TT1
Renick, PJ1
Pulse, ME1
Weiss, WJ1
Huang, HC1
Shieh, CC1
Yu, WL1
Cheng, KC1
Chen, CC1
Chang, ST1
Chuang, YC1
Agar, SL1
Baze, WB1
Olano, JP1
Fadl, AA1
Foltz, SM1
Suarez, G1
Motin, VL1
Chauhan, S1
Klimpel, GR1
Peterson, JW1
Valero, G1
Moreno, F1
Graybill, JR1
Klemens, SP1
Sharpe, CA1
Rogge, MC1
Cynamon, MH1
McDermott-Lancaster, RD2
Banerjee, DK2
Tomioka, H2
Saito, H2
Behrens-Baumann, W1
Padełskaya, EN1
Mikamo, H1
Kawazoe, K1
Sato, Y1
Izumi, K1
Tamaya, T1
Nichterlein, T1
Bornitz, F1
Kretschmar, M1
Hof, H1
Moreau, JM1
Green, LC1
Engel, LS1
Hill, JM1
Benner, GE1
Andrews, GP1
Strachan, SD1
Sample, AK1
Heath, DG1
Friedlander, AM1
Osada, T1
Yamamura, K1
Fujimoto, K1
Mizuno, K1
Sakurai, T1
Ohta, M1
Nabeshima, T1
Onyeji, CO1
Bui, KQ2
Owens, RC1
Nicolau, DP2
Quintiliani, R2
Nightingale, CH2
Fukuda, M1
Inoue, A1
Sasaki, K1
Brieland, JK1
Loebenberg, D1
Menzel, F1
Hare, RS1
Isogai, E2
Isogai, H2
Hayashi, S2
Kubota, T2
Kimura, K2
Fujii, N2
Ohtani, T1
Sato, K2
Yanagihara, K1
Tomono, K1
Sawai, T1
Kuroki, M1
Kaneko, Y1
Ohno, H1
Higashiyama, Y1
Miyazaki, Y1
Hirakata, Y1
Maesaki, S1
Tashiro, T1
Kohno, S1
Melki, SA1
Safar, A1
Yaghouti, F1
Scharper, P1
Scharper, M1
Zeligs, B1
MacDowell, AL1
Goldberg, MA1
Lustbader, J1
Rao, SN1
Fong, Y1
Kampmeier, J1
LaBree, LD1
Tanzer, DJ1
Joly-Guillou, ML1
Wolff, M1
Farinotti, R1
Bryskier, A1
Carbon, C1
Xuan, D1
Zhong, M1
Mattoes, H1
McNabb, J1
Destache, CJ1
Pakiz, CB1
Larsen, C1
Owens, H1
Dash, AK1
Hirose, K1
Takeshi, K1
Oguma, K1
Cambau, E1
Bonnafous, P1
Perani, E1
Sougakoff, W1
Ji, B2
Jarlier, V1
Paggi, AM1
Kamysz, W1
Kasprzykowski, F1
Mackiewicz, Z1
Szabó, D1
Máthé, A1
Lengyel, J1
Anderlik, P1
Rókusz, L1
Rozgonyi, F1
Vaudaux, P1
Francois, P1
Bisognano, C1
Schrenzel, J1
Lew, DP1
Perani, EG1
Petinon, C1
Ohadi, C1
Litwin, KL1
Moreira, H1
Kwitko, S1
Gauderman, WJ1
Gritz, DC2
Gwon, A2
Jones, R1
Sanders, CC1
Lee, TY1
Tang-Liu, D1
Hubbard, BB1
Vallée, E3
Azoulay-Dupuis, E3
Pocidalo, JJ3
Bergogne-Bérézin, E1
Bedos, JP2
Padeĭskaia, EN1
Mnatsakanian, VE1
Hardy, DJ1
Swanson, RN1
Wegener, A1
Kuhn, UD1
Lorenz, M1
Hockwin, O1
Nakajima, R1
Hashimoto, S1
Iigo, Y1
Ishida, Y1
Une, T2
Osada, Y2
Fujimoto, T1
Katami, K1
Tsumura, M1
Tachizawa, H1

Reviews

3 reviews available for ofloxacin and Disease Models, Animal

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
[Ofloxacin in mycobacteriosis therapy].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1997, Volume: 42, Issue:11

    Topics: Animals; Anti-Infective Agents; Clinical Trials as Topic; Disease Models, Animal; Humans; Leprosy, T

1997
Review of preclinical studies with ofloxacin.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1992, Volume: 14, Issue:2

    Topics: Animals; Bacteria; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Mic

1992

Trials

1 trial available for ofloxacin and Disease Models, Animal

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021

Other Studies

116 other studies available for ofloxacin and Disease Models, Animal

ArticleYear
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
    Journal of medicinal chemistry, 2010, May-13, Volume: 53, Issue:9

    Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological

2010
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
    European journal of medicinal chemistry, 2012, Volume: 47, Issue:1

    Topics: Animals; Blood-Brain Barrier; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease

2012
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
    Science translational medicine, 2019, 07-10, Volume: 11, Issue:500

    Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S

2019
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49

    Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr

2020
Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
    European journal of medicinal chemistry, 2022, Jun-05, Volume: 236

    Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Disease Models, Animal; Memantine; Mice; Recepto

2022
A novel mouse model of chronic suppurative otitis media and its use in preclinical antibiotic evaluation.
    Science advances, 2020, Volume: 6, Issue:33

    Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Humans; Mice; Ofloxacin; Otitis Media, Suppu

2020
Effects of Kolaviron on Pneumonia-like Infection Induced in Albino Wistar Rats.
    Anti-inflammatory & anti-allergy agents in medicinal chemistry, 2021, Volume: 20, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Disease Models, Animal; Dose-Response Rela

2021
Treatment with a neutrophil elastase inhibitor and ofloxacin reduces P. aeruginosa burden in a mouse model of chronic suppurative otitis media.
    NPJ biofilms and microbiomes, 2021, 04-06, Volume: 7, Issue:1

    Topics: Animals; Antigens, Ly; Disease Models, Animal; Drug Synergism; Female; Flow Cytometry; Humans; Machi

2021
Plasmodium-Salmonella Coinfection Induces Intense Inflammatory Response, Oxidative Stress, and Liver Damage: A Mice Model Study for Therapeutic Strategy.
    Shock (Augusta, Ga.), 2018, Volume: 50, Issue:6

    Topics: Animals; Anti-Bacterial Agents; Antimalarials; Coinfection; Cytokines; Disease Models, Animal; Liver

2018
Lipid metabolism disorder induced by up-regulation of miR-125b and miR-144 following β-diketone antibiotic exposure to F0-zebrafish (Danio rerio).
    Ecotoxicology and environmental safety, 2018, Nov-30, Volume: 164

    Topics: Animals; Anti-Bacterial Agents; Atherosclerosis; Chlortetracycline; Cholesterol; Ciprofloxacin; Comp

2018
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.
    American journal of respiratory and critical care medicine, 2013, Jul-01, Volume: 188, Issue:1

    Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Disease

2013
In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests.
    The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:12

    Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Resistance, Bacterial; Female; Fluoroqu

2016
Effect of iNOS inhibitor LNMMA along with antibiotics Chloramphenicol or Ofloxacin in murine peritoneal macrophages regulates S.aureus infection as well as inflammation: An in vitro study.
    Microbial pathogenesis, 2017, Volume: 105

    Topics: Animals; Anti-Bacterial Agents; Antioxidants; Chloramphenicol; Cyclooxygenase 2; Cytokines; Disease

2017
Bactericidal activity of the combination of levofloxacin with rifampin in experimental prosthetic knee infection in rabbits due to methicillin-susceptible Staphylococcus aureus.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Therapy, Combination; Humans; Knee Pros

2009
[Bacterial corneal ulcer treated with intrastromal antibiotic. Experimental model in vivo].
    Archivos de la Sociedad Espanola de Oftalmologia, 2009, Volume: 84, Issue:3

    Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cornea;

2009
Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:8

    Topics: Animals; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Epithelium; Fe

2009
Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:9

    Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Aztreonam; Disease Models, Ani

2009
Intracellular antimicrobial activity appearing as a relevant factor in antibiotic efficacy against an experimental foreign-body infection caused by Staphylococcus aureus.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Cloxacillin; Colony Count, Microbial; Cytoplasm; Disease Models, Ani

2009
[Efficacy of levofloxacin, lomefloxacin and moxifloxacin vs. other fluoroquinolones in experimental plague due to FI+ and FI- strains of Yersinia pestis in Albino mice].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2009, Volume: 54, Issue:5-6

    Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, D

2009
[Therapeutic efficacy of levofloxacin against a model of replicable Legionella pneumophila lung infection in DBA/2 mice].
    The Japanese journal of antibiotics, 2009, Volume: 62, Issue:5

    Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Resistance, Bacte

2009
Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model.
    The Journal of infectious diseases, 2010, Mar-15, Volume: 201, Issue:6

    Topics: Acinetobacter baumannii; Amikacin; Animals; Anti-Bacterial Agents; Cefepime; Cephalosporins; Disease

2010
Efficacy of antimicrobial polymer coatings in an animal model of bacterial infection associated with foreign body implants.
    The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Disease Models, Animal; Female; Foreign Bod

2010
Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models.
    Acta ophthalmologica, 2010, Volume: 88, Issue:4

    Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Colony Count, Mic

2010
Novel mucoadhesive polysaccharide isolated from Bletilla striata improves the intraocular penetration and efficacy of levofloxacin in the topical treatment of experimental bacterial keratitis.
    The Journal of pharmacy and pharmacology, 2010, Volume: 62, Issue:9

    Topics: Absorption; Administration, Topical; Animals; Anti-Bacterial Agents; Aqueous Humor; Bacterial Load;

2010
Immunological, antioxidative, and morphological response in combined treatment of ofloxacin and Lactobacillus fermentum ME-3 probiotic in Salmonella Typhimurium murine model.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2010, Volume: 118, Issue:11

    Topics: Animals; Anti-Bacterial Agents; Cytokines; Disease Models, Animal; Glutathione Peroxidase; Glutathio

2010
In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:4

    Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bridged-Ring Compounds; Cell Line; Cells, Cultured; Cl

2011
Levofloxacin cures experimental pneumonic plague in African green monkeys.
    PLoS neglected tropical diseases, 2011, Feb-08, Volume: 5, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Bacteremia; Chlorocebus aethiops; Disease Models, Animal; Infusions,

2011
Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.
    American journal of respiratory and critical care medicine, 2011, Jul-15, Volume: 184, Issue:2

    Topics: Adrenergic Uptake Inhibitors; Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Bacterial

2011
Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin.
    The Journal of antibiotics, 2012, Volume: 65, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line; Chromatography, High Pressure Liquid; Dise

2012
[Efficacy and tolerance of rezonizate in complex with fluoroquinolones or mycobutin on a model of experimental murine tuberculosis].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2011, Volume: 56, Issue:7-8

    Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Drug Therapy, Combination; Drug Tolera

2011
Critical appraisal of air pouch infection model in rats.
    Annals of clinical and laboratory science, 2012,Winter, Volume: 42, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Dose-Re

2012
A peptide based on homologous sequences of the β-barrel assembly machinery component BamD potentiates antibiotic susceptibility of Pseudomonas aeruginosa.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:9

    Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Bacterial Outer Membrane Proteins; Blotting, Western

2012
Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.
    Clinical and vaccine immunology : CVI, 2012, Volume: 19, Issue:8

    Topics: Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antigens, Bacteri

2012
[Protection and mechanism of Fagopyrum cymosum on lung injury in rats with Klebsiella pneumonia].
    Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, 2012, Volume: 35, Issue:4

    Topics: Animals; Chemokine CXCL2; Cytokines; Disease Models, Animal; Drugs, Chinese Herbal; Fagopyrum; Immun

2012
A non-invasive in vivo imaging system to study dissemination of bioluminescent Yersinia pestis CO92 in a mouse model of pneumonic plague.
    Microbial pathogenesis, 2013, Volume: 55

    Topics: Animals; Animals, Outbred Strains; Anti-Bacterial Agents; Disease Models, Animal; Female; Flow Cytom

2013
Moxifloxacin as postoperative prophylaxis for Enterococcus faecalis-induced endophthalmitis after cataract surgery in aphakic rabbits.
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2013, Volume: 29, Issue:4

    Topics: Administration, Ophthalmic; Animals; Anti-Bacterial Agents; Aphakia, Postcataract; Aza Compounds; Di

2013
Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.
    Toxins, 2013, Jan-14, Volume: 5, Issue:1

    Topics: Adjuvants, Immunologic; Administration, Inhalation; Animals; Anthrax; Anthrax Vaccines; Anti-Bacteri

2013
Optimal treatment of systemic bacillus Calmette-Guérin infection: investigations in an animal model.
    The Journal of urology, 2002, Volume: 168, Issue:2

    Topics: Animals; Cell Survival; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, Drug; Dru

2002
Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
    The Journal of antimicrobial chemotherapy, 2002, Volume: 50, Issue:3

    Topics: Animals; Anti-Infective Agents; Area Under Curve; Disease Models, Animal; Genotype; Humans; Levoflox

2002
Quinupristin/dalfopristin bonding in combination with intraperitoneal antibiotics prevent infection of knitted polyester graft material in a subcutaneous rat pouch model infected with resistant Staphylococcus epidermidis.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2002, Volume: 24, Issue:3

    Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Disease Models, Anima

2002
Corneal flap complications in refractive surgery: Part 2: postoperative treatments of diffuse lamellar keratitis in an experimental animal model.
    Journal of cataract and refractive surgery, 2003, Volume: 29, Issue:4

    Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Corneal Stroma; Disease Mod

2003
Reply to: Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
    The Journal of antimicrobial chemotherapy, 2003, Volume: 51, Issue:5

    Topics: Animals; Anti-Infective Agents; Disease Models, Animal; Levofloxacin; Ofloxacin; Penicillin Resistan

2003
Treatment with rokitamycin suppresses the lethality in a murine model of Escherichia coli O157:H7 infection.
    International journal of antimicrobial agents, 2003, Volume: 21, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Colony Count, Microbial; Disease Models, Anim

2003
Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model.
    American journal of ophthalmology, 2003, Volume: 136, Issue:1

    Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Disease Mode

2003
Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2003, Volume: 22, Issue:11

    Topics: Animals; Disease Models, Animal; DNA, Bacterial; Dose-Response Relationship, Drug; Drug Resistance,

2003
A comparison of invasive and cytotoxic Pseudomonas aeruginosa strain-induced corneal disease responses to therapeutics.
    Current eye research, 2003, Volume: 27, Issue:5

    Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Cornea; Corneal Ulcer; Disease Models, Anim

2003
Treatment of experimental bacterial keratitis with topical trovafloxacin.
    Archives of ophthalmology (Chicago, Ill. : 1960), 2004, Volume: 122, Issue:1

    Topics: Administration, Topical; Animals; Anti-Infective Agents; Biological Availability; Ciprofloxacin; Col

2004
Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
    Chemotherapy, 2004, Volume: 50, Issue:2

    Topics: Abdominal Abscess; Animals; Anti-Bacterial Agents; Aza Compounds; Bacteroides fragilis; Bacteroides

2004
Novel murine model of pneumococcal pneumonia: use of temperature as a measure of disease severity to compare the efficacies of moxifloxacin and levofloxacin.
    Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:9

    Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Body Temperature; Colony Count, Microbial; Disease Mo

2004
Effects of G-CSF and antibiotic prophylaxis in a 2 x 2 factorial design on outcome in septic rats.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2004, Volume: 53 Suppl 2

    Topics: Abdomen; Animals; Antibiotic Prophylaxis; Cefuroxime; Clinical Trials as Topic; Disease Models, Anim

2004
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    International journal of antimicrobial agents, 2005, Volume: 25, Issue:2

    Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DN

2005
Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model.
    Current eye research, 2005, Volume: 30, Issue:3

    Topics: Administration, Topical; Animals; Anti-Infective Agents, Local; Cefazolin; Ciprofloxacin; Colony Cou

2005
Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomy.
    Journal of cataract and refractive surgery, 2005, Volume: 31, Issue:7

    Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Transplantat

2005
Antibiotic-induced release of inflammatory mediators from bacteria in experimental Klebsiella pneumoniae-induced sepsis.
    Folia microbiologica, 2005, Volume: 50, Issue:2

    Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftazidime; Disease Models, Animal; Endotoxins; Humans; I

2005
[Ofloxacin efficacy in the prophylaxis and treatment of experimental plague due to antigen complete and defective strains of the pathogen].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2002, Volume: 47, Issue:3

    Topics: Animals; Anti-Bacterial Agents; Antigens, Bacterial; Disease Models, Animal; Mice; Mutation; Ofloxac

2002
In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa.
    Journal of chemotherapy (Florence, Italy), 2005, Volume: 17, Issue:4

    Topics: Amikacin; Animals; Ceftazidime; Disease Models, Animal; Drug Resistance, Bacterial; Drug Synergism;

2005
Modulation of gastric hemorrhage and ulceration by oxidative stress and histamine release in Salmonella typhimurium-infected rats.
    Inflammopharmacology, 2005, Volume: 13, Issue:1-3

    Topics: Allopurinol; Animals; Antioxidants; Dimethyl Sulfoxide; Disease Models, Animal; Gastric Juice; Gastr

2005
Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
    Current eye research, 2006, Volume: 31, Issue:1

    Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count,

2006
Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
    International journal of antimicrobial agents, 2006, Volume: 27, Issue:4

    Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; DNA

2006
Role of topical fluoroquinolones on the pathogenesis of diffuse lamellar keratitis in experimental in vivo studies.
    Journal of cataract and refractive surgery, 2006, Volume: 32, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Corneal Stroma; Disease Models, Animal; Endotoxins; F

2006
Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy?
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacterial Outer Membrane Proteins; Disease Models,

2006
Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model.
    Eye (London, England), 2007, Volume: 21, Issue:7

    Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Ciprofloxacin; Disease Models, Animal;

2007
The effect of proteolytic enzyme serratiopeptidase in the treatment of experimental implant-related infection.
    The Journal of bone and joint surgery. American volume, 2006, Volume: 88, Issue:6

    Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Dru

2006
Antibiotic effects of WP-0405, a thermo-setting ofloxacin gel, on methicillin-resistant Staphylococcus aureus keratitis in rabbits.
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2006, Volume: 22, Issue:4

    Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aqueous Humor; Biological Availability; Cil

2006
Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:12

    Topics: Acetamides; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cloxacillin; Disease Models, Anim

2006
[Comparative study of treatment with quinupristin-dalfopristin alone or in combination with gentamicin, teicoplanin, imipenem or levofloxacin in experimental endocarditis due to a multidrug-resistant Enterococcus faecium].
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2006, Volume: 19, Issue:3

    Topics: Aged; Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Resistance, Multiple, Bacterial;

2006
Dissociation between inhibition and killing by levofloxacin in human granulocytic anaplasmosis.
    Vector borne and zoonotic diseases (Larchmont, N.Y.), 2006,Winter, Volume: 6, Issue:4

    Topics: Aged; Anaplasma phagocytophilum; Anaplasmosis; Animals; Anti-Bacterial Agents; Disease Models, Anima

2006
Cytotoxic effects of the fluoroquinolone ofloxacin on stromal keratocytes.
    Cornea, 2007, Volume: 26, Issue:2

    Topics: Animals; Anti-Infective Agents; Corneal Stroma; Disease Models, Animal; Eye Infections, Bacterial; H

2007
Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice.
    Journal of chemotherapy (Florence, Italy), 2006, Volume: 18, Issue:6

    Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Body Temperature; Colony Count, Microbial; Disease

2006
Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:4

    Topics: Administration, Inhalation; Aerosols; Animals; Anthrax; Anti-Bacterial Agents; Antibiotic Prophylaxi

2007
Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
    Journal of cardiovascular electrophysiology, 2007, Volume: 18, Issue:6

    Topics: Action Potentials; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Ani

2007
Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7

    Topics: Acute Disease; Animals; Anti-Bacterial Agents; Ciprofloxacin; Cricetinae; Disease Models, Animal; Do

2007
Role of interleukin-6 in the pathogenesis of an avian model of Staphylococcus aureus arthritis.
    Poultry science, 2007, Volume: 86, Issue:6

    Topics: Animals; Anti-Bacterial Agents; Arthritis, Infectious; Chickens; Disease Models, Animal; Interleukin

2007
Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7

    Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combi

2007
Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:8

    Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Disease Models, Animal; Drug Resistance, Ba

2007
Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha.
    Toxicological sciences : an official journal of the Society of Toxicology, 2007, Volume: 100, Issue:1

    Topics: Alanine Transaminase; Animals; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Diseas

2007
Simultaneous determination of rifampicin and levofloxacin concentrations in catheter segments from a mouse model of a device-related infection by liquid chromatography/electrospray ionization tandem mass spectrometry.
    Journal of pharmaceutical and biomedical analysis, 2008, Mar-13, Volume: 46, Issue:4

    Topics: Animals; Anti-Bacterial Agents; Catheters, Indwelling; Chromatography, High Pressure Liquid; Disease

2008
Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries.
    Respirology (Carlton, Vic.), 2008, Volume: 13, Issue:1

    Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cytokines; Disease Models, Animal; Flu

2008
Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague.
    Infection and immunity, 2008, Volume: 76, Issue:4

    Topics: Animals; Anti-Bacterial Agents; Cytokines; Disease Models, Animal; Female; Levofloxacin; Lipoprotein

2008
Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against Mycobacterium simiae in murine model of disseminated infection.
    Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:11

    Topics: Animals; Clarithromycin; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Male; Mice;

1994
Activity of levofloxacin in a murine model of tuberculosis.
    Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:7

    Topics: Animals; Antitubercular Agents; Culture Media; Disease Models, Animal; Dose-Response Relationship, D

1994
Activity of sparfloxacin against Mycobacterium leprae measured by the proportional bactericidal test.
    International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 1993, Volume: 61, Issue:4

    Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Colony Count, Microbial; Disease Models, Anim

1993
Therapeutic efficacy of some new quinolones and a combination of ofloxacin with rifampin against Mycobacterium leprae infection induced in athymic nude mice.
    International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 1993, Volume: 61, Issue:2

    Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Female; Leprosy; Mice; Mice, Inbred BALB

1993
Absorption of topically administered ciprofloxacin, ofloxacin and gentamicin in the inflamed rabbit eye.
    Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 1996, Volume: 210, Issue:2

    Topics: Absorption; Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aqueous

1996
Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis.
    The Journal of antimicrobial chemotherapy, 1998, Volume: 41, Issue:1

    Topics: Animals; Anti-Infective Agents; Bacteroides fragilis; Disease Models, Animal; Drug Therapy, Combinat

1998
Successful treatment of murine listeriosis and salmonellosis with levofloxacin.
    Journal of chemotherapy (Florence, Italy), 1998, Volume: 10, Issue:4

    Topics: Animals; Anti-Infective Agents; Cephalosporins; Disease Models, Animal; Dose-Response Relationship,

1998
Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model.
    Current eye research, 1998, Volume: 17, Issue:8

    Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Disease Models, Anim

1998
Immune response to Yersinia outer proteins and other Yersinia pestis antigens after experimental plague infection in mice.
    Infection and immunity, 1999, Volume: 67, Issue:4

    Topics: Animals; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Bacterial Outer Membrane

1999
Prophylaxis of local vascular graft infection with levofloxacin incorporated into albumin-sealed dacron graft (LVFX-ALB Graft).
    Microbiology and immunology, 1999, Volume: 43, Issue:4

    Topics: Albumins; Animals; Anti-Infective Agents; Bacterial Adhesion; Blood Vessel Prosthesis Implantation;

1999
Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia.
    International journal of antimicrobial agents, 1999, Volume: 12, Issue:2

    Topics: Acute Kidney Injury; Administration, Cutaneous; Animals; Anti-Infective Agents; Bacteremia; Ciproflo

1999
[An animal model of corneal bacterial infection induced by intra-corneal injection of Staphylococcus epidermidis].
    Nippon Ganka Gakkai zasshi, 1999, Volume: 103, Issue:7

    Topics: Animals; Anti-Infective Agents; Corneal Diseases; Disease Models, Animal; Injections; Ofloxacin; Rab

1999
Efficacy of SCH27899 in an animal model of Legionnaires' disease using immunocompromised A/J mice.
    Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:5

    Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cortisone; Dis

2000
Effect of antibiotics, levofloxacin and fosfomycin, on a mouse model with Escherichia coli O157 infection.
    Microbiology and immunology, 2000, Volume: 44, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Toxins; Diarrhea; Disease Models, A

2000
Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation.
    The Journal of antimicrobial chemotherapy, 2000, Volume: 46, Issue:1

    Topics: Animals; Biofilms; Chronic Disease; Clarithromycin; Disease Models, Animal; Drug Therapy, Combinatio

2000
Effect of topical povidone-iodine versus topical ofloxacin on experimental Staphylococcus keratitis.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2000, Volume: 238, Issue:5

    Topics: Animals; Anti-Infective Agents; Colony Count, Microbial; Cornea; Disease Models, Animal; Eye Infecti

2000
The effectiveness of a topical antibiotic irrigating solution in a model of staphylococcal keratitis after lamellar keratectomy.
    American journal of ophthalmology, 2000, Volume: 130, Issue:1

    Topics: Administration, Topical; Animals; Anti-Infective Agents; Colony Count, Microbial; Corneal Stroma; Co

2000
In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia.
    The Journal of antimicrobial chemotherapy, 2000, Volume: 46, Issue:5

    Topics: Acinetobacter Infections; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Area Unde

2000
Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:3

    Topics: Animals; Anti-Infective Agents; Aza Compounds; Disease Models, Animal; Female; Fluoroquinolones; Lev

2001
Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model.
    The Journal of antimicrobial chemotherapy, 2001, Volume: 47, Issue:5

    Topics: Animals; Anti-Infective Agents; Area Under Curve; Disease Models, Animal; Levofloxacin; Meningitis,

2001
Therapeutic effect of anti-TNF-alpha antibody and levofloxacin (LVFX) in a mouse model of enterohemorrhagic Escherichia coli O157 infection.
    Comparative immunology, microbiology and infectious diseases, 2001, Volume: 24, Issue:4

    Topics: Animals; Anti-Infective Agents; Antibodies, Bacterial; Antibodies, Monoclonal; Disease Models, Anima

2001
Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Jan-01, Volume: 34, Issue:1

    Topics: Adult; Aged; Antibiotics, Antitubercular; Disease Models, Animal; DNA Gyrase; DNA-Directed RNA Polym

2002
Therapeutic efficacy of intraperitoneal polymyxin B and polymyxin-like peptides alone or combined with levofloxacin in rat models of septic shock.
    The Journal of antimicrobial chemotherapy, 2002, Volume: 49, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Disease Models, Animal; Drug Therapy, Combina

2002
In vitro and in vivo activities of ciprofloxacin and levofloxacin against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.
    Current medicinal chemistry, 2002, Volume: 9, Issue:4

    Topics: Animals; Anti-Infective Agents; beta-Lactamases; Ciprofloxacin; Colony Count, Microbial; Disease Mod

2002
Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus.
    Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Disease Models, Anima

2002
Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice.
    International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 1992, Volume: 60, Issue:4

    Topics: Animals; Clarithromycin; Disease Models, Animal; Female; Fluoroquinolones; Foot; Hindlimb; Immunocom

1992
Anti-inflammatory therapy and outcome in a guinea pig model of Pseudomonas keratitis.
    Cornea, 1992, Volume: 11, Issue:5

    Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dicarboxylic Acids; Disease

1992
An experimental study to evaluate the bactericidal activity of ofloxacin against an established Mycobacterium leprae infection.
    International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 1992, Volume: 60, Issue:3

    Topics: Animals; Dapsone; Disease Models, Animal; Drug Therapy, Combination; Leprosy; Mice; Mice, Nude; Myco

1992
Topical ofloxacin in the treatment of Pseudomonas keratitis in a rabbit model.
    Cornea, 1992, Volume: 11, Issue:2

    Topics: Administration, Topical; Animals; Aqueous Humor; Chromatography, High Pressure Liquid; Disease Model

1992
Pharmacokinetics of four fluoroquinolones in an animal model of infected lung.
    The Journal of antimicrobial chemotherapy, 1991, Volume: 28 Suppl C

    Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones; Lung Diseas

1991
Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafloxacin.
    The Journal of antimicrobial chemotherapy, 1991, Volume: 28 Suppl C

    Topics: Acute Disease; Animals; Anti-Infective Agents; Disease Models, Animal; Female; Fluoroquinolones; Mic

1991
Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria.
    Tubercle, 1991, Volume: 72, Issue:3

    Topics: Animals; Disease Models, Animal; Female; Fleroxacin; Leprosy; Mice; Mice, Inbred BALB C; Microbial S

1991
[Activity of fluoroquinolones studied on a model of suppurative meningoencephalitis caused by Pseudomonas aeruginosa in mice].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1991, Volume: 36, Issue:7

    Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Microbial; E

1991
Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.
    The Journal of infectious diseases, 1991, Volume: 163, Issue:2

    Topics: Amoxicillin; Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Erythromycin; Fe

1991
Evaluation of a possible cocataractogenic potential of Ofloxacin.
    Lens and eye toxicity research, 1990, Volume: 7, Issue:1

    Topics: Animals; Cataract; Diabetes Mellitus, Experimental; Disease Models, Animal; Evaluation Studies as To

1990
Chemotherapeutic efficacy of ofloxacin against experimental pneumonia with Pseudomonas aeruginosa in guinea pigs.
    Arzneimittel-Forschung, 1989, Volume: 39, Issue:6

    Topics: Animals; Disease Models, Animal; Female; Guinea Pigs; Immunosuppression Therapy; Lung; Ofloxacin; Pn

1989
Chemotherapeutic efficacy of ofloxacin on renal and subcutaneous infection models with Staphylococcus aureus in mice.
    Chemotherapy, 1986, Volume: 32, Issue:3

    Topics: Abscess; Animals; Anti-Bacterial Agents; Autoradiography; Disease Models, Animal; Kinetics; Male; Mi

1986